Sex-Related Outcomes After Drug-Eluting Stent Should We “Never Mind” or “Mind” the Gap?⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology. by Mehran, Roxana & Kini, Annapoorna S.
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ex-Related Outcomes After
rug-Eluting Stent
hould We “Never Mind” or “Mind” the Gap?*
oxana Mehran, MD, Annapoorna S. Kini, MD
ew York, New York
ardiovascular disease (CVD) is the single most common
ause of death among women. Although over the past 40
ears age-adjusted mortality for CVD in Western countries
as decreased, the decline among women is more modest
han that of men (1). Moreover, life expectancy has in-
reased, especially in women and, therefore, the prevalence
f CVD has increased in this population (2). Age-adjusted
npatient mortality after percutaneous coronary intervention
PCI) in the Nationwide Inpatient Sample database de-
lined between 1995 and 2004, but women continue to have
igher mortality rates (3).
See page 1250
Clinical outcome of women after PCI has been challeng-
ng. Historically, female sex has been associated with in-
reased complications during and after PCI (4,5). Women
ndergoing PCI usually present with more comorbid con-
itions, including hypertension, older age, elevated choles-
erol, more complex and diffuse coronary disease, and longer
eferral time compared with men (5–7). This makes the
omparison between men and women nearly impossible.
ith the significant improvements in angioplasty tech-
iques, the introduction of drug-eluting stents (DES), and
he availability of small-size stents, the previously noted sex
ap in outcomes seems to have narrowed. Nevertheless, can
e claim this with statistical confidence?
In the current issue of JACC: Cardiovascular Interventions,
ikhail et al. (8) try to tackle this question by diving deeply
nto the databases of all paclitaxel-eluting stent (PES)
tudies. The authors used patient-based pooled data and
tatistical analytical methods to compare men and women in
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai
chool of Medicine, New York, New York. Dr. Mehran is a consultant for Cardiva,
ordis, The Medicines Company, Regado Biosciences, and she received researchp
rant from Bristol-Myers Squibb/sanofi-aventis. Dr. Kini reports that she has no
elationships to disclose.he PES studies with long-term follow-up (up to 5 years in
andomized and 2 years in registry studies). This is the best
hat can be done with their available data. But is this
nough? Can we really say that PES is effective in the same
anner in men versus women? Although close to 10,000
atients were studied in these well-controlled trials, women
epresented only a small minority of the population. There-
ore, the true comparative effectiveness study of PES versus
are-metal stent in women was based on only 1,050 female
ubjects (655 PES vs. 395 bare-metal stent) and was hardly
owered to answer the question of safety and efficacy of PES
n women.
Mikhail et al. (8) elegantly analyzed all their PES data
nd showed that, although the number of female patients in
tudies has been small (generally under 30%), PES seem to
e similarly efficacious in both sexes. In fact, long-term
esults seem to show favorable results for definite/probable
tent thrombosis during the first year in women with PES.
an any of this be definitively proven?
One can never tell, because the numbers continue to be
mall and not powered to study women.
Inclusion of women in clinical trials for PCI has been a
ery well-established and important deficiency in the ever-
rowing clinical trials network in interventional cardiology
3). This challenge is complicated by the well-established
omorbid conditions in women compared with men that
ight exclude women from “Simple-Vanilla” studies. How-
ver, even in trials of more complex lesion subsets (the
o-called “all comer” studies), we continue to observe a
ower enrollment rate of women. This might be secondary
o the fact that the prevalence of disease is lower for the
ame age compared with men (9). However, more complex
ocioeconomic reasons that might explain why women are
ore reluctant to enroll in studies have not been evaluated.
t is our responsibility to better understand these issues by
esearching and designing studies for women with data
lements that are relevant to women. This is one of the
nitiatives that are being organized by the U.S. government
Food and Drug Administration, Office of Women’s
ealth) and professional societies (Society for Cardiovas-
ular Angiography and Interventions/Women in Innova-
ions, American College of Cardiology, European Society of
ardiology, and American Heart Association).
Another important issue not really addressed by Mikhail
t al. (8) is that women continue to be at risk for important
ascular and bleeding complications after PCI (10–13).
ith the more potent antithrombotic/antiplatelet agents,
he susceptibility of bleeding and complications for women
ill increase. Furthermore, chronic use of such oral agents
fter PCI with DES and the need to stop these medications
ue to bleeding in women more often than men have not
een fully evaluated. The use of anticoagulants with im-
roved safety profiles (i.e., less bleeding) in the female
opulation would be prudent but is not yet studied, except
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1261or sub-group, post hoc, underpowered analyses in women
13,14). A detailed bleeding risk profile assessment in the
emale population undergoing PCI would be prudent to
inimize these complications. Finally, dedicated studies
eed to be performed for evaluation of the utility of risk
core assessment in choosing antithrombotic/antiplatelet
gents in the female population.
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